Researcher index

Authors in the psilocybin and psilocin literature

Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.

Timo Torsten Schmidt

32 indexed publications match this author name.

ORCID: 0000-0003-1612-1301
OpenAlex: https://openalex.org/A5013656947

Author watchlist

Create a confirmed email alert for new publications matching this author.

Topics

Depression 14 Receptor Pharmacology 12 Anxiety 10 Consciousness 9 Mechanism of Action 7 Observational Study 6 Mystical Experience 6 Brain Imaging 5 Review Article 4 Emotional Processing 4 Biomarkers 3 Treatment-Resistant Depression 3

Journals

PsyArXiv 6 Journal of psychopharmacology (Oxford, England) 3 Research Square 2 bioRxiv 2 Fortschritte der Neurologie-Psychiatrie 2 Molecular Psychiatry 1 eLife 1 Universität Zürich, ZORA 1

Publication history

α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in miceMolecular Psychiatry · 2026-07-07 Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronseLife · 2026-03-27 Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsResearch Square · 2026-01-07 Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch NegativitybioRxiv · 2025-11-07 Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigmUniversität Zürich, ZORA · 2025-11-05 [Acceptance of psilocybin-assisted therapy in German-speaking countries].Der Nervenarzt · 2025-11-01 Akzeptanz psilocybin-assistierter Therapie in den deutschsprachigen Ländernedoc Publication server (Humboldt University of Berlin) · 2025-02-12 The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelicsPsyArXiv · 2024-10-22 The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelicsPsyArXiv · 2024-10-22 Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch NegativityResearch Square · 2024-09-26 Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.Med (New York, N.Y.) · 2024-03-08 The Altered Xperience Project (AXP): Quantitative and Qualitative Data from a Citizen Science Initiative on the Subjective Experience of Altered States of ConsciousnessPsyArXiv · 2023-06-04 The Altered Xperience Project (AXP): Quantitative and Qualitative Data from a Citizen Science Initiative on the Subjective Experience of Altered States of ConsciousnessPsyArXiv · 2023-06-04 ID: 212703 Augmenting rTMS With Psilocybin-Assisted Psychotherapy (PAP) for PTSD: A Proof-of-Concept Study DesignNeuromodulation Technology at the Neural Interface · 2023-06-01 [Attitudes of Mental Health Experts Towards Psilocybin].Fortschritte der Neurologie-Psychiatrie · 2023-03-01 The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics.Therapeutic advances in psychopharmacology · 2023-01-01 Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI).PloS one · 2022-01-01 Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy.American journal of psychotherapy · 2021-12-01 Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI)PsyArXiv · 2021-04-02 Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI)PsyArXiv · 2021-04-02 Dose-response relationships of psilocybin-induced subjective experiences in humans.Journal of psychopharmacology (Oxford, England) · 2021-04-01 How does it feel to be on psilocybin? Dose-response relationships of subjective experiences in humansbioRxiv · 2020-06-11 [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].Fortschritte der Neurologie-Psychiatrie · 2017-07-01 Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.Journal of psychopharmacology (Oxford, England) · 2016-12-01 The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.NeuroImage. Clinical · 2016-01-01 Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?Journal of psychopharmacology (Oxford, England) · 2015-03-01 Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.Cerebral cortex (New York, N.Y.: 1991) · 2014-12-01 Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.The Journal of neuroscience: the official journal of the Society for Neuroscience · 2013-06-19 Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on α Oscillations, N170 Visual-Evoked Potentials, and Visual HallucinationsOpen MIND · 2013-01-01 The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.Psychopharmacology · 2013-01-01 Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.Biological psychiatry · 2012-12-01 Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2012-03-01

Author directory